Skip to main
GNFT
GNFT logo

GNFT Stock Forecast & Price Target

GNFT Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 20%
Strong Sell 0%

Bulls say

Genfit SA is advancing its strategic position in the biotechnology sector with the anticipated approvals of Iqirvo in key EU markets, potentially unlocking a €26.5 million milestone payment from Ipsen, contingent on pricing and reimbursement approvals. The positive outcomes from the pivotal Phase 3 ELATIVE trial, where Iqirvo met its primary composite endpoint, underscore the robustness of the clinical data supporting its marketing authorization for Primary Biliary Cholangitis (PBC). Additionally, a recent royalty financing agreement with HealthCare Royalty could provide up to €185 million in funding, enhancing Genfit's financial position and supporting ongoing development efforts in innovative medicines and diagnostic solutions.

Bears say

Genfit SA faces considerable risks related to the timely progress of its clinical and regulatory efforts, particularly concerning its lead product, Iqirvo, which is crucial for the company's growth. Delays in clinical and regulatory timelines, along with potential failures to secure necessary approvals in new markets, could significantly hinder the company’s market potential and revenue generation. Additionally, unforeseen challenges in the commercial landscape for Iqirvo may adversely impact Genfit's financial outlook and investor confidence.

GNFT has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genfit - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genfit - ADR (GNFT) Forecast

Analysts have given GNFT a Buy based on their latest research and market trends.

According to 5 analysts, GNFT has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genfit - ADR (GNFT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.